"10.1371_journal.pone.0052772","plos one","2012-12-26T00:00:00Z","Praveen Papareddy; Martina Kalle; Ole E Sørensen; Katarina Lundqvist; Matthias Mörgelin; Martin Malmsten; Artur Schmidtchen","Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Biomedical Center, Lund, Sweden; Division of Infection Medicine, Department of Clinical Sciences, Lund University, Biomedical Center, Lund, Sweden; Department of Pharmacy, Uppsala University, Uppsala, Sweden","Conceived and designed the experiments: PP AS. Performed the experiments: PP MK OS KL M. Mörgelin M. Malmsten. Analyzed the data: PP AS. Contributed reagents/materials/analysis tools: KL M. Malmsten. Wrote the paper: PP AS.","Drs. Malmsten and Schmidtchen are co-founders of, and own shares in XImmune AB, a company developing peptides for anti-infective treatment. The TFPI-2 peptide EDC34 is included in a patent application of the company. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","12","Praveen Papareddy","PP",7,TRUE,2,5,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
